Fmr LLC increased its position in Celgene Corporation (NASDAQ:CELG) by 5.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,594,467 shares of the biopharmaceutical company’s stock after buying an additional 697,250 shares during the period. Fmr LLC owned about 1.61% of Celgene worth $1,635,643,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Norinchukin Bank The increased its position in Celgene by 4.7% during the first quarter. Norinchukin Bank The now owns 90,401 shares of the biopharmaceutical company’s stock worth $11,249,000 after purchasing an additional 4,024 shares during the last quarter. Quantitative Investment Management LLC acquired a new stake in shares of Celgene in the first quarter worth $7,104,000. Peoples Bank OH increased its position in shares of Celgene by 3.1% in the first quarter. Peoples Bank OH now owns 4,067 shares of the biopharmaceutical company’s stock worth $506,000 after acquiring an additional 124 shares in the last quarter. Budros Ruhlin & Roe Inc. increased its position in shares of Celgene by 6.6% in the first quarter. Budros Ruhlin & Roe Inc. now owns 4,050 shares of the biopharmaceutical company’s stock worth $504,000 after acquiring an additional 250 shares in the last quarter. Finally, Carret Asset Management LLC increased its position in shares of Celgene by 2.9% in the first quarter. Carret Asset Management LLC now owns 9,030 shares of the biopharmaceutical company’s stock worth $1,124,000 after acquiring an additional 255 shares in the last quarter. 79.48% of the stock is owned by institutional investors and hedge funds.

CELG has been the subject of several recent research reports. Morgan Stanley lowered shares of Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective for the company. in a research report on Thursday, October 5th. BTIG Research reissued a “hold” rating on shares of Celgene in a research report on Sunday, October 22nd. Cantor Fitzgerald reissued a “hold” rating and issued a $112.00 price objective on shares of Celgene in a research report on Monday, October 30th. Vetr raised shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price objective for the company in a research report on Monday, October 23rd. Finally, Citigroup Inc. lowered shares of Celgene from a “buy” rating to a “neutral” rating in a research report on Friday, October 20th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have issued a buy rating and two have given a strong buy rating to the stock. Celgene currently has a consensus rating of “Buy” and a consensus target price of $139.57.

Celgene Corporation (CELG) opened at $104.50 on Friday. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. Celgene Corporation has a 52-week low of $94.55 and a 52-week high of $147.17. The stock has a market cap of $82,274.63, a PE ratio of 16.33, a PEG ratio of 0.81 and a beta of 1.79.

Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The business had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter last year, the company earned $1.58 EPS. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. research analysts anticipate that Celgene Corporation will post 6.67 earnings per share for the current year.

In related news, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the sale, the director now owns 85,551 shares of the company’s stock, valued at approximately $12,110,599.56. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Terrie Curran sold 1,727 shares of the stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the sale, the insider now directly owns 3,925 shares in the company, valued at approximately $564,768.25. The disclosure for this sale can be found here. In the last ninety days, insiders sold 20,227 shares of company stock worth $2,843,956. Corporate insiders own 0.95% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Fmr LLC Has $1.64 Billion Stake in Celgene Corporation (CELG)” was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.watchlistnews.com/fmr-llc-has-1-64-billion-stake-in-celgene-corporation-celg/1726800.html.

Celgene Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.